aod9604 stimulates lipolysis adipocytes Inside the Science of AOD 9604: A Peptide AOD-9604 - Peptide for Fat

Improvements in chronic fatigue due to B12 injections can be noticed as early as one week

The COR-I trial, involving 1,742 participants over 56 weeks, demonstrated 6.1% average weight loss with Contrave versus 1.3% with placebo (Greenway et al., Obesity, 2010)

For instance, those with severe vitamin B12 deficiency may require weekly or biweekly shots until their blood levels return to normal

Originally created as a lipolytic compound for treating obesity, AOD-9604 has demonstrated potential in animal studie

While cyanocobalamin can still raise blood levels, it may not act as quickly or effectively in neurological tissue